Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.
The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.
Haemonetics EVP and Chief Commercial Officer Roy Galvin reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. He received a grant of 27,535 shares of common stock in the form of RSUs under the company’s long-term incentive plan. These RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third anniversary. On the same date, 879 shares valued at $56.29 per share were withheld to cover tax obligations tied to vesting RSUs, rather than sold on the open market. Following these transactions, he directly holds 12,347 shares of common stock, a figure that includes unvested RSUs previously reported and 415 shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan.
Haemonetics Corp senior vice president of human resources Laurie A. Miller reported routine equity compensation activity involving company common stock. She received a grant of 13,323 shares valued at zero cost to her, reflecting the vesting or award of restricted stock units under the company’s long-term incentive plan.
In a related move, 948 shares at $56.29 each were withheld to cover tax obligations tied to the RSU vesting, a non-market transaction rather than an open-market sale. After these transactions, she directly holds 27,977 shares of Haemonetics common stock.
Haemonetics Corp President & CEO Christopher Simon reported compensation-related equity activity. He received an award of 78,344 shares of common stock in the form of restricted stock units that vest over three years. On the same date, 9,681 shares were withheld to cover tax obligations tied to previously vesting RSUs, and his reported direct holdings after these transactions were in the hundreds of thousands of shares.
North Peak group and related persons filed an amended Schedule 13G/A reporting ownership of 5 percent or less of Haemonetics Corp. The filing is a joint statement by North Peak Capital Management, North Peak Capital GP, several North Peak funds, and Jeremy S. Kahan and Michael K. Kahan.
The cover lists the class as Common stock, $0.01 par value with CUSIP 405024100. The filing cites joint filing arrangements and states each Reporting Person disclaims beneficial ownership beyond the group description; signatures are dated 05/13/2026.
Haemonetics reported fourth quarter and fiscal 2026 results and issued fiscal 2027 guidance. Fourth quarter revenue was $346.4 million, up 4.8%, while fiscal 2026 revenue was $1.33 billion, down 2.0% from fiscal 2025.
Due mainly to a $77.2 million impairment related to Attune Medical and other charges, the company posted a fourth quarter net loss of $20.1 million, or $(0.44) per diluted share, versus earnings of $1.17 a year earlier. Adjusted diluted EPS for the quarter rose to $1.29, and fiscal 2026 adjusted diluted EPS was $4.96.
Operating cash flow for fiscal 2026 was $293.2 million and free cash flow was $209.9 million. In the fourth quarter, the company repurchased 1.58 million shares for $100 million, leaving $325 million under its authorization. For fiscal 2027, Haemonetics guides to 4–7% reported revenue growth, 3–6% organic revenue growth and about 80% free cash flow conversion.
Haemonetics EVP and CFO James DArecca reported a small tax-related share disposition. On May 1, 2026, 655 shares of Haemonetics common stock were withheld at $59.26 per share to cover tax obligations from vesting restricted stock units. This was not an open-market sale. After the withholding, DArecca directly owned 27,637 shares, which includes previously reported unvested RSUs.
Haemonetics Corporation reports that long-serving director Charles J. Dockendorff has informed the company he will not stand for re-election at its 2026 Annual Meeting of Shareholders. He has served on the Board since 2014 and is a member of the Audit Committee and the Governance and Compliance Committee.
Mr. Dockendorff will continue as a director and in his committee roles until the 2026 Annual Meeting. The company states that his decision not to stand for re-election is not the result of any disagreement with Haemonetics.
Vanguard Capital Management reported beneficial ownership of 2,445,817 shares of Haemonetics Corp Common Stock, representing 5.26% of the class. The filing states Vanguard has sole dispositive power over 2,445,817 shares and sole voting power for 355,428 shares. The statement discloses that these holdings include securities held for Vanguard funds and managed accounts and is signed by Ashley Grim.
Haemonetics Corp reports that Vanguard Portfolio Management beneficially owns 2,600,145 shares of Common Stock. The filing states this equals 5.59% of the class and shows sole dispositive power over 2,600,145 shares with sole voting power for 40,829 shares. The Schedule 13G disclosure is signed by Ashley Grim.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting 0 shares and 0% beneficial ownership of Haemonetics Corp common stock. The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries report ownership separately under SEC Release No. 34-39538. The filing is signed by Ashley Grim as Head of Global Fund Administration on March 27, 2026.